Test Code 1HIV / 34949-Q HIV-1 GENOTYPING
Additional Codes
Software | Test Code |
---|---|
SoftID | 1HIV |
EPIC | LAB20158 |
Quest Diagnostics | 34949-Q |
Performing Laboratory
Quest Diagnostics
Method Name
DNA Sequencing, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Reference Values
An interpretive report will be issued
Report Available
5-10 Days
Specimen Type
Submit one of the following:
~ Cerebrospinal Fluid (CSF)
~ Plasma
Preferred Container
Lavender Top Tube (EDTA) – EDTA plasma
Sterile Container – Container should be leakproof
Preferred Volume
Cerebrospinal Fluid (CSF): 2 mL (Sterile Container)
Plasma: 2 mL (Lavender Top Tube (EDTA))
Minimum Volume
Cerebrospinal Fluid (CSF): 0.6 mL (Sterile Container)
Plasma: 0.6 mL (Lavender Top Tube (EDTA))
Specimen Collection and Handling
Submit one of the following:
BLOOD: Separate plasma from cells within 24 hours of collection by centrifugation. Transfer to a standard aliquot tube with a screw top cap. Ship frozen.
CSF: Transfer to a standard aliquot tube with a screw top cap. Ship frozen.
Specimen Stability Information
Specimen Type: Cerebrospinal Fluid (CSF)
Frozen: 42 Days
Refrigerated: 6 Days
Room Temp: 24 Hours
Must be spun/separated within: 24 Hours
Specimen Type: Plasma
Frozen: 42 Days
Refrigerated: 6 Days
Room Temp: 24 Hours
Must be spun/separated within: 24 Hours
Add On Capable
Yes
Advance Beneficiary Notice Requirements
No ABN Required
CPT Code Information
CPT Code |
CPT Description |
CPT Disclaimer |
---|---|---|
87900 | Infectious Agent Drug Susceptibility Phenotype Prediction Using Regularly Updated Genotypic Bioinformatics | |
87901 | Infectious Agent Drug Susceptibility Phenotype Prediction Using Regularly Updated Genotypic Bioinformatics, HIV-1, Reverse Transcriptase and Protease Regions |
Performing Laboratory Location
Quest Diagnostics
LOINC Code Information
48558-1
Clinical Significance
This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test identifies drug resistance-associated mutations in the HIV-1 protease and reverse transcriptase genes. It can be used to predict antiretroviral drug resistance before initiation of therapy and in patients experiencing virologic failure while on therapy.
LIMITATIONS:
An infection is often composed of a variety of strains of the virus. The test may identify only the predominant type of virus thus leaving the minority viruses to thrive once the predominant type is treated. Lack of resistance may not confer susceptibilities.
Rejection Information
Plasma received frozen in the plasma preparation tube (PPT); Serum sample; Whole blood >24 hours old; Frozen whole blood